Role of oral rifampcin in central serous chorioretinopathy (CSCR) | 54804
Journal of Clinical and Experimental Ophthalmology

Journal of Clinical and Experimental Ophthalmology
Open Access

ISSN: 2155-9570

+44 1223 790975

Role of oral rifampcin in central serous chorioretinopathy (CSCR): Study of 31 cases

10th International Conference on Clinical & Experimental Ophthalmology

November 21-23, 2016 Dubai, UAE

Sameen Afzal Junejo

Liaquat University of Medical and Health Sciences, Pakistan

Scientific Tracks Abstracts: J Clin Exp Ophthalmol

Abstract :

Central serous chorioretinopathy (CSCR) is characterized by accumulation of fluid in between sensory retina and retinal pigment epithelium. Chronic CSCR present with frequent exacerbations and a poor visual prognosis. Various therapeutic measures are available for recent onset and recurrent/chronic CSR. Thus, novel therapies to combat this frustrating disorder are needed. We will present fifteen cases with recent and chronic CSCR treated with oral rifampcin that completely resolved with 1 month of oral rifampcin therapy. As a cytochrome P450, 3A4 inducer, rifampin is thought to favorably alter the metabolism of endogenous steroids, thereby leading to an improvement in CSCR manifestations. The study of 31 cases of CSCR treated with half adult dose oral rifampcin will be presented.

Biography :

Sameen Afzal Junejo Taken up fellowship FCPS from College of Physicians and Surgeons Pakistan in 1999. Published 27 papers in reputed journals. Interested in anterior segment and adenexia. Introduced new techniques in Phacoemulsification cataract surgery. At present working as Professor Institute of ophthalmology LUMHS-JAMSHORO, Pakistan.